NYBC Ventures — 2024 Investments

2 investments dated 2024 · listed companies and verified rows first · show all

AvenCellavencell.com in 𝕏Oct 2024 · $112M

AvenCell Therapeutics develops next-generation cell therapies for hard-to-treat cancers, including solid tumors, combining switchable universal CAR-T technology with a CRISPR/Cas9-based allogeneic platform.

BiotechLongevityMedical Devices

Andrew Schiermeier(Chief Executive Officer)in

Co-investorsNovo Holdings Blackstone Life Sciences Eight Roads Ventures F-Prime Capital Ligand Pharmaceuticals

Veraloxveralox.comNov 2024acquired by Cadrenal Therapeutics · Dec 2025 · $200K

Developing novel treatments based on the 12-LOX pathway for immuno-inflammatory diseases.

Co-investorsAlumni Ventures Hatteras Venture Partners Pappas Capital Sanofi Ventures Alexandria Genesys Capital +4 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.